Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Stereoselectivity in pharmacokinetics of rivoglitazone, a novel peroxisome proliferator-activated receptor γ agonist, in rats and monkeys: model-based pharmacokinetic analysis and in vitro-in vivo extrapolation approach.

Izumi T, Tsuruta F, Ishizuka T, Nakamura K, Kothuma M, Takahashi M.

J Pharm Sci. 2013 Sep;102(9):3174-88. doi: 10.1002/jps.23586. Epub 2013 May 19.

PMID:
23686684
2.

Pharmacokinetics, metabolism, and disposition of rivoglitazone, a novel peroxisome proliferator-activated receptor γ agonist, in rats and monkeys.

Uchiyama M, Iwabuchi H, Tsuruta F, Abe K, Takahashi M, Koda H, Oguchi M, Okazaki O, Izumi T.

Drug Metab Dispos. 2011 Apr;39(4):653-66. doi: 10.1124/dmd.110.036194. Epub 2010 Dec 21.

3.

In vitro metabolism of rivoglitazone, a novel peroxisome proliferator-activated receptor γ agonist, in rat, monkey, and human liver microsomes and freshly isolated hepatocytes.

Uchiyama M, Koda H, Fischer T, Mueller J, Yamamura N, Oguchi M, Iwabuchi H, Okazaki O, Izumi T.

Drug Metab Dispos. 2011 Jul;39(7):1311-9. doi: 10.1124/dmd.111.038729. Epub 2011 Apr 21.

4.

Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, in obese diabetic rodent models.

Kanda S, Nakashima R, Takahashi K, Tanaka J, Ogawa J, Ogata T, Yachi M, Araki K, Ohsumi J.

J Pharmacol Sci. 2009 Oct;111(2):155-66. Epub 2009 Oct 6.

5.

The disposition and metabolism of naveglitazar, a peroxisome proliferator-activated receptor alpha-gamma dual, gamma-dominant agonist in mice, rats, and monkeys.

Yi P, Hadden CE, Annes WF, Jackson DA, Peterson BC, Gillespie TA, Johnson JT.

Drug Metab Dispos. 2007 Jan;35(1):51-61. Epub 2006 Sep 29.

6.
7.

Pharmacokinetic properties of TDP4815 after single intravenous and oral administrations to rat, rabbit, monkey, dog and in vitro drug metabolism.

Chen Y, Cheng D, Tio C, Kagan N, Eisennagel S, Dasgupta M, Tomczuk B, Bone R, Huebert N.

Biopharm Drug Dispos. 2008 Apr;29(3):127-38. doi: 10.1002/bdd.592.

PMID:
18186144
8.

Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys.

Hosagrahara VP, Chandrasena G, Chang SY, Koplowitz B, Hariharan N, Cheng PT, Humphreys WG.

Xenobiotica. 2006 Dec;36(12):1227-38.

PMID:
17162469
9.

Model-based development of a PPARgamma agonist, rivoglitazone, to aid dose selection and optimize clinical trial designs.

Rohatagi S, Carrothers TJ, Jin J, Jusko WJ, Khariton T, Walker J, Truitt K, Salazar DE.

J Clin Pharmacol. 2008 Dec;48(12):1420-9. doi: 10.1177/0091270008323260. Epub 2008 Oct 20.

PMID:
18936283
10.

Dose-independent pharmacokinetics of a new peroxisome proliferator-activated receptor-γ agonist, KR-62980, in Sprague-Dawley rats and ICR mice.

Park JS, Kim MS, Song JS, Choi SH, Lee BH, Woo J, Ahn JH, Bae MA, Ahn SH.

Arch Pharm Res. 2011 Dec;34(12):2051-8. doi: 10.1007/s12272-011-1207-8. Epub 2011 Dec 31.

PMID:
22210030
11.

Human plasma concentrations of cytochrome P450 probes extrapolated from pharmacokinetics in cynomolgus monkeys using physiologically based pharmacokinetic modeling.

Shida S, Utoh M, Murayama N, Shimizu M, Uno Y, Yamazaki H.

Xenobiotica. 2015;45(10):881-6. doi: 10.3109/00498254.2015.1028511. Epub 2015 Jun 15.

PMID:
26075833
12.

Metabolic fate of sipoglitazar, a novel oral PPAR agonist with activities for PPAR-γ, -α and -δ, in rats and monkeys and comparison with humans in vitro.

Nishihara M, Sudo M, Kamiguchi H, Kawaguchi N, Maeshiba Y, Kiyota Y, Takahashi J, Tagawa Y, Kondo T, Asahi S.

Drug Metab Pharmacokinet. 2012;27(2):223-31. Epub 2011 Nov 29.

13.
14.

Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.

Kamath AV, Wang J, Lee FY, Marathe PH.

Cancer Chemother Pharmacol. 2008 Mar;61(3):365-76. Epub 2007 Apr 11.

PMID:
17429625
15.

Rivoglitazone: a new thiazolidinedione for the treatment of type 2 diabetes mellitus.

Koffarnus RL, Wargo KA, Phillippe HM.

Ann Pharmacother. 2013 Jun;47(6):877-85. doi: 10.1345/aph.1R754. Epub 2013 Apr 30. Review.

PMID:
23632280
16.

Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist.

Vachharajani NN, Yeleswaram K, Boulton DW.

J Pharm Sci. 2003 Apr;92(4):760-72.

PMID:
12661062
17.

Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.

Yang Z, Zadjura L, D'Arienzo C, Marino A, Santone K, Klunk L, Greene D, Lin PF, Colonno R, Wang T, Meanwell N, Hansel S.

Biopharm Drug Dispos. 2005 Dec;26(9):387-402.

PMID:
16142720
18.

Pharmacokinetics of troglitazone, an antidiabetic agent: prediction of in vivo stereoselective sulfation and glucuronidation from in vitro data.

Izumi T, Hosiyama K, Enomoto S, Sasahara K, Sugiyama Y.

J Pharmacol Exp Ther. 1997 Mar;280(3):1392-400.

19.

Human pharmacokinetics and interconversion of enantiomers of MK-0767, a dual PPARalpha/gamma agonist.

Rippley RK, Yan KX, Matthews ND, Greenberg HE, Herman GA, Wagner JA.

J Clin Pharmacol. 2007 Mar;47(3):323-33.

PMID:
17322144
20.

A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes.

Kong AP, Yamasaki A, Ozaki R, Saito H, Asami T, Ohwada S, Ko GT, Wong CK, Leung GT, Lee KF, Yeung CY, Chan JC.

Diabetes Obes Metab. 2011 Sep;13(9):806-13. doi: 10.1111/j.1463-1326.2011.01411.x.

PMID:
21492364

Supplemental Content

Support Center